

























![]()
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis April 27, 2026 8:00 AM EDT
Company Participants
Alan Lada - VP of IR & Capital Markets
Lawrence Klein - President, CEO & Director
Joana Goncalves - Chief Medical Officer
Conference Call Participants
Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division
Yatin Suneja - Guggenheim Securities, LLC, Research Division
Tyler Van Buren - TD Cowen, Research Division
Kaiyue Yang - UBS Investment Bank, Research Division
Samuel Slutsky - LifeSci Capital, LLC, Research Division
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Xiaotong Jia - Jefferies LLC, Research Division
Julian Harrison - BTIG, LLC, Research Division
Etzer Darout - Barclays Bank PLC, Research Division
Brandon Frith - Wolfe Research, LLC
Yu Fan - Wedbush Securities Inc., Research Division
Presentation
Operator
Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oruka Therapeutics presentation of Interim data from EVERLAST-A. [Operator Instructions]
I would now like to turn the call over to Alan Lada. Please go ahead.
Alan Lada
VP of IR & Capital Markets
Thank you, operator. Please note that during this call, we'll be making forward-looking statements related to our current expectations and plans for the company and our clinical programs. These statements represent our views as of this call are subject to risks and uncertainties such as the final data from the Phase IIa clinical trial not being consistent with the interim data presented today, regulatory feedback regarding the company's planned clinical trials and other risks covered in our SEC filings. These forward-looking statements should not be relied upon as representing our views as of any date in the future. Please review carefully.
I'll now turn the call over to our
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。